Skip to main content
Top
Published in: Dermatology and Therapy 1/2022

Open Access 01-01-2022 | Alopecia Areata | Original Research

Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata

Authors: Kathleen W. Wyrwich, Randall Winnette, Randall Bender, Kavita Gandhi, Nicole Williams, Nimanee Harris, Lauren Nelson

Published in: Dermatology and Therapy | Issue 1/2022

Login to get access

Abstract

Introduction

Individuals with alopecia areata (AA) may experience significant impacts on their health-related quality of life. The novel Alopecia Areata Patient Priority Outcomes (AAPPO) questionnaire has been developed to assess hair loss signs, emotional symptoms, and activity limitations associated with AA. The objective of this study was to evaluate psychometric properties and establish scoring of the AAPPO in adults and adolescents with AA.

Methods

Scoring and measurement properties of the AAPPO were examined using baseline and 2-week follow-up data from a prospective, noninterventional, web-based study of 121 patients with AA (85 adults aged ≥ 18 years, 36 adolescents aged 12–17 years) with Severity of Alopecia Tool (SALT) ≥ 25% scalp hair loss.

Results

Exploratory and confirmatory factor analysis supported four single Hair Loss (HL) items, an Emotional Symptoms domain (ES; 4 items), and an Activity Limitations domain (AL; 3 items). Among all patients, the multi-item ES and AL domains had strong internal consistency (α ≥ 0.87); all HL items and domain scores had strong test-retest reliability (weighted kappa or intraclass correlation coefficients ≥ 0.78). All HL item scores demonstrated strong construct validity (r ≥ 0.52) compared with the patient-reported Alopecia Areata Symptom and Impact Scale (AASIS) hair loss subscale score; ES and AL domain scores exhibited strong construct validity (r ≥ 0.66) compared with the SF-36 Mental Component Summary (MCS) score. Using SALT scores, HL mean item scores were better (lower) in the 25–49% SALT subgroup versus those with highest SALT scores (76–100%); however, ES mean domain scores were better in the SALT 76–100% subgroup in the same comparison (p < 0.0001). Using AASIS and MCS score–created subgroups, ES and AL mean domain scores demonstrated hypothesized differences across subgroups (all p values < 0.0001).

Conclusion

The AAPPO questionnaire is a reliable, valid disease-specific measure of hair loss severity and impact in individuals with AA.
Appendix
Available only for authorised users
Literature
1.
go back to reference Benigno M, Anastassopoulos KP, Mostaghimi A, Udall M, Daniel SR, Cappelleri JC, et al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clin Cosmet Investig Dermatol. 2020;13:259–66.CrossRef Benigno M, Anastassopoulos KP, Mostaghimi A, Udall M, Daniel SR, Cappelleri JC, et al. A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clin Cosmet Investig Dermatol. 2020;13:259–66.CrossRef
2.
go back to reference Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992;26(6):926–31.CrossRef Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol. 1992;26(6):926–31.CrossRef
3.
go back to reference Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol. 1993;29(4):568–75.CrossRef Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol. 1993;29(4):568–75.CrossRef
4.
go back to reference Ruiz-Doblado S, Carrizosa A, Garcia-Hernandez MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol. 2003;42(6):434–7.CrossRef Ruiz-Doblado S, Carrizosa A, Garcia-Hernandez MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol. 2003;42(6):434–7.CrossRef
5.
go back to reference Skogberg G, Jackson S, Astrand A. Mechanisms of tolerance and potential therapeutic interventions in Alopecia Areata. Pharmacol Ther. 2017;179:102–10.CrossRef Skogberg G, Jackson S, Astrand A. Mechanisms of tolerance and potential therapeutic interventions in Alopecia Areata. Pharmacol Ther. 2017;179:102–10.CrossRef
7.
go back to reference Winnette R, Martin S, Harris N, Deal L. Development of the alopecia areata patient priority outcomes instrument, a new patient reported outcome measure. J Am Acad Dermatol. 2019;81(4 (suppl 1)):AB46. Winnette R, Martin S, Harris N, Deal L. Development of the alopecia areata patient priority outcomes instrument, a new patient reported outcome measure. J Am Acad Dermatol. 2019;81(4 (suppl 1)):AB46.
9.
go back to reference Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines—part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440–7.CrossRef Olsen EA, Hordinsky MK, Price VH, Roberts JL, Shapiro J, Canfield D, et al. Alopecia areata investigational assessment guidelines—part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440–7.CrossRef
10.
go back to reference Buckley J, Rapini RP. Totalis alopecia. Treasure Island: StatPearls; 2020. Buckley J, Rapini RP. Totalis alopecia. Treasure Island: StatPearls; 2020.
11.
go back to reference Burroway B, Griggs J, Tosti A. Alopecia totalis and universalis long-term outcomes: a review. J Eur Acad Dermatol Venereol. 2020;34(4):709–15.CrossRef Burroway B, Griggs J, Tosti A. Alopecia totalis and universalis long-term outcomes: a review. J Eur Acad Dermatol Venereol. 2020;34(4):709–15.CrossRef
13.
go back to reference Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol. 1999;40(2 Pt 1):242–6.CrossRef Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol. 1999;40(2 Pt 1):242–6.CrossRef
14.
go back to reference Mendoza TR, Osei J, Duvic M. The utility and validity of the alopecia areata symptom impact scale in measuring disease-related symptoms and their effect on functioning. J Investig Dermatol Symp Proc. 2018;19(1):S41–6.CrossRef Mendoza TR, Osei J, Duvic M. The utility and validity of the alopecia areata symptom impact scale in measuring disease-related symptoms and their effect on functioning. J Investig Dermatol Symp Proc. 2018;19(1):S41–6.CrossRef
15.
go back to reference Ware JEJ. How to score the revised MOS short-form health scales. Boston: Institute for the Improvement of Medical Care and Health; 1988. Ware JEJ. How to score the revised MOS short-form health scales. Boston: Institute for the Improvement of Medical Care and Health; 1988.
16.
go back to reference Maruish MEE. User’s manual for the SF-36v2 Health Survey. 3rd ed. Lincoln: QualityMetric Incorporated; 2011. Maruish MEE. User’s manual for the SF-36v2 Health Survey. 3rd ed. Lincoln: QualityMetric Incorporated; 2011.
17.
go back to reference SAS Institute I. SAS proprietary software, version 9.4. Cary (NC); 2012. SAS Institute I. SAS proprietary software, version 9.4. Cary (NC); 2012.
18.
go back to reference Dean K, Walker Z, Jenkinson C. Data quality, floor and ceiling effects, and test-retest reliability of the Mild Cognitive Impairment Questionnaire. Patient Relat Outcome Meas. 2018;9:43–7.CrossRef Dean K, Walker Z, Jenkinson C. Data quality, floor and ceiling effects, and test-retest reliability of the Mild Cognitive Impairment Questionnaire. Patient Relat Outcome Meas. 2018;9:43–7.CrossRef
19.
go back to reference Muthén LK, Muthén BO. Mplus user’s guide. 7th ed. Los Angeles: Muthén & Muthén; 1998-2015. Muthén LK, Muthén BO. Mplus user’s guide. 7th ed. Los Angeles: Muthén & Muthén; 1998-2015.
20.
go back to reference Browne MW, Cudeck R. Alternative ways of assessing model fit. In: Bollen KA, Long JS, editors. Testing structural equation models. Newbury Park: Sage; 1993. Browne MW, Cudeck R. Alternative ways of assessing model fit. In: Bollen KA, Long JS, editors. Testing structural equation models. Newbury Park: Sage; 1993.
21.
go back to reference Steiger JH. Structural model evaluation and modification: an interval estimation approach. Multivar Behav Res. 1990;25(2):173–80.CrossRef Steiger JH. Structural model evaluation and modification: an interval estimation approach. Multivar Behav Res. 1990;25(2):173–80.CrossRef
22.
go back to reference Bentler PM. EQS structural equations program manual. Los Angeles: BMDP Statistical Software; 1989. Bentler PM. EQS structural equations program manual. Los Angeles: BMDP Statistical Software; 1989.
23.
go back to reference Tucker LR, Lewis C. A reliability coefficient for maximum likelihood factor analysis. Psychometrika. 1973;38(1):1–10.CrossRef Tucker LR, Lewis C. A reliability coefficient for maximum likelihood factor analysis. Psychometrika. 1973;38(1):1–10.CrossRef
24.
go back to reference Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model. 1999;6(1):1–55.CrossRef Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives. Struct Equ Model. 1999;6(1):1–55.CrossRef
25.
go back to reference Schumacker RE, Lomax RG. A beginner’s guide to structural equation modeling. Mahwah: Erlbaum; 1996. Schumacker RE, Lomax RG. A beginner’s guide to structural equation modeling. Mahwah: Erlbaum; 1996.
26.
go back to reference Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas. 1973;33:613–9.CrossRef Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas. 1973;33:613–9.CrossRef
27.
go back to reference Streiner DL, Norman GR, Cairney J. Health Measurement Scales: a practical guide to their development and use. 5th ed. Oxford: Oxford University Press; 2015.CrossRef Streiner DL, Norman GR, Cairney J. Health Measurement Scales: a practical guide to their development and use. 5th ed. Oxford: Oxford University Press; 2015.CrossRef
28.
go back to reference Warrens M. Some paradoxical results for the quadratically weighted kappa. Psychometrika. 2012;77(2):315–23.CrossRef Warrens M. Some paradoxical results for the quadratically weighted kappa. Psychometrika. 2012;77(2):315–23.CrossRef
29.
go back to reference McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30–46.CrossRef McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30–46.CrossRef
30.
go back to reference Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–8.CrossRef Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420–8.CrossRef
31.
go back to reference Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRef Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–74.CrossRef
32.
go back to reference Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.
33.
go back to reference Food and Drug Administration (FDA). Methods to identify what is important to patients and select, develop or modify fit-for-purpose clinical outcomes assessments. Patient-focused drug development guidance public workshop. October 15–16 2018. https://www.fda.gov/media/116281/download. Accessed 4 Feb 2020. Food and Drug Administration (FDA). Methods to identify what is important to patients and select, develop or modify fit-for-purpose clinical outcomes assessments. Patient-focused drug development guidance public workshop. October 15–16 2018. https://​www.​fda.​gov/​media/​116281/​download. Accessed 4 Feb 2020.
34.
go back to reference Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.CrossRef Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16:297–334.CrossRef
35.
go back to reference Cappelleri JC, Zou KH, Bushmakin AG, Alvir JM, Alemayehu D, Symonds T. Patient-reported outcomes: measurement, implementation and interpretation. Cambridge: CRC Press; 2013.CrossRef Cappelleri JC, Zou KH, Bushmakin AG, Alvir JM, Alemayehu D, Symonds T. Patient-reported outcomes: measurement, implementation and interpretation. Cambridge: CRC Press; 2013.CrossRef
36.
go back to reference Hays R, Prince-Embury S, Chen H. HIS: RAND-36 health status inventory. San Antonio: The Psychological Corporation; 1998. Hays R, Prince-Embury S, Chen H. HIS: RAND-36 health status inventory. San Antonio: The Psychological Corporation; 1998.
38.
go back to reference Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42(4):549–66.CrossRef Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42(4):549–66.CrossRef
39.
go back to reference Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et al. Development of the Scalp Hair Assessment PRO measure for alopecia areata. Br J Dermatol. 2020;183(6):1065–72.CrossRef Wyrwich KW, Kitchen H, Knight S, Aldhouse NVJ, Macey J, Nunes FP, et al. Development of the Scalp Hair Assessment PRO measure for alopecia areata. Br J Dermatol. 2020;183(6):1065–72.CrossRef
40.
go back to reference Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in Alopecia Areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62–8.CrossRef Mesinkovska N, King B, Mirmirani P, Ko J, Cassella J. Burden of illness in Alopecia Areata: a cross-sectional online survey study. J Investig Dermatol Symp Proc. 2020;20(1):S62–8.CrossRef
41.
go back to reference Taft C, Karlsson J, Sullivan M. Do SF-36 summary component scores accurately summarize subscale scores? Qual Life Res. 2001;10(5):395–404.CrossRef Taft C, Karlsson J, Sullivan M. Do SF-36 summary component scores accurately summarize subscale scores? Qual Life Res. 2001;10(5):395–404.CrossRef
42.
go back to reference Laucis NC, Hays RD, Bhattacharyya T. Scoring the SF-36 in orthopaedics: a brief guide. J Bone Jt Surg Am. 2015;97(19):1628–34.CrossRef Laucis NC, Hays RD, Bhattacharyya T. Scoring the SF-36 in orthopaedics: a brief guide. J Bone Jt Surg Am. 2015;97(19):1628–34.CrossRef
43.
go back to reference Fabbrocini G, Panariello L, De Vita V, Vincenzi C, Lauro C, Nappo D, et al. Quality of life in alopecia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol. 2013;27(3):e276–81.CrossRef Fabbrocini G, Panariello L, De Vita V, Vincenzi C, Lauro C, Nappo D, et al. Quality of life in alopecia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol. 2013;27(3):e276–81.CrossRef
44.
go back to reference Endo Y, Miyachi Y, Arakawa A. Development of a disease-specific instrument to measure quality of life in patients with alopecia areata. Eur J Dermatol. 2012;22(4):531–6.CrossRef Endo Y, Miyachi Y, Arakawa A. Development of a disease-specific instrument to measure quality of life in patients with alopecia areata. Eur J Dermatol. 2012;22(4):531–6.CrossRef
45.
go back to reference Chernyshov PV, Tomas-Aragones L, Finlay AY, Manolache L, Marron SE, Sampogna F, et al. Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. J Eur Acad Dermatol Venereol. 2021;35(8):1614–21.CrossRef Chernyshov PV, Tomas-Aragones L, Finlay AY, Manolache L, Marron SE, Sampogna F, et al. Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. J Eur Acad Dermatol Venereol. 2021;35(8):1614–21.CrossRef
Metadata
Title
Validation of the Alopecia Areata Patient Priority Outcomes (AAPPO) Questionnaire in Adults and Adolescents with Alopecia Areata
Authors
Kathleen W. Wyrwich
Randall Winnette
Randall Bender
Kavita Gandhi
Nicole Williams
Nimanee Harris
Lauren Nelson
Publication date
01-01-2022
Publisher
Springer Healthcare
Keyword
Alopecia Areata
Published in
Dermatology and Therapy / Issue 1/2022
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-021-00648-z

Other articles of this Issue 1/2022

Dermatology and Therapy 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.